ATE483466T1 - Fas peptid-mimetika und ihre verwendungszwecke - Google Patents

Fas peptid-mimetika und ihre verwendungszwecke

Info

Publication number
ATE483466T1
ATE483466T1 AT03729102T AT03729102T ATE483466T1 AT E483466 T1 ATE483466 T1 AT E483466T1 AT 03729102 T AT03729102 T AT 03729102T AT 03729102 T AT03729102 T AT 03729102T AT E483466 T1 ATE483466 T1 AT E483466T1
Authority
AT
Austria
Prior art keywords
fas
peptide mimetics
receptor
mimetics
exocyclic
Prior art date
Application number
AT03729102T
Other languages
English (en)
Inventor
Mark Greene
Ramachandran Murali
Akihiro Hasegawa
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE483466T1 publication Critical patent/ATE483466T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT03729102T 2002-05-23 2003-05-23 Fas peptid-mimetika und ihre verwendungszwecke ATE483466T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38330902P 2002-05-23 2002-05-23
US46594303P 2003-04-28 2003-04-28
PCT/US2003/016325 WO2003099845A2 (en) 2002-05-23 2003-05-23 Fas peptide mimetics and uses thereof

Publications (1)

Publication Number Publication Date
ATE483466T1 true ATE483466T1 (de) 2010-10-15

Family

ID=29587001

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729102T ATE483466T1 (de) 2002-05-23 2003-05-23 Fas peptid-mimetika und ihre verwendungszwecke

Country Status (8)

Country Link
US (3) US7288519B2 (de)
EP (1) EP1513543B1 (de)
JP (1) JP4405916B2 (de)
AT (1) ATE483466T1 (de)
AU (1) AU2003233662B2 (de)
CA (1) CA2490542C (de)
DE (1) DE60334452D1 (de)
WO (1) WO2003099845A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209297A1 (en) * 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
AU2003233662B2 (en) 2002-05-23 2010-04-01 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
MX2007008326A (es) * 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
WO2009089362A1 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Methods of treatment using agents for regulating fas receptor function in skin and hair related pathologies
EP2324355B1 (de) * 2008-08-28 2014-01-22 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
KR101646726B1 (ko) * 2013-08-12 2016-08-09 한양대학교 산학협력단 환형 폴리 ｆｔｐ 및 이의 용도
US10189887B2 (en) * 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
KR101909906B1 (ko) * 2015-11-13 2018-10-22 한양대학교 산학협력단 비강 투여를 통한 뇌졸중 치료용 조성물
SG11202105650RA (en) * 2018-12-04 2021-06-29 Signet Biotech Inc Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis
CN110746485A (zh) * 2019-10-09 2020-02-04 天津科技大学 新型碱性蛋白酶抑制肽的筛选
CN111138513B (zh) * 2020-01-06 2022-10-18 天津科技大学 谷氨酰胺转氨酶交联肽的筛选
WO2022086039A1 (ko) * 2020-10-19 2022-04-28 주식회사 시그넷바이오텍 Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
KR20230057747A (ko) 2021-10-22 2023-05-02 한양대학교 산학협력단 세포사멸 억제 단백질을 포함하는 허혈성 뇌졸중 예방 또는 치료용 조성물

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL83549C (de) * 1952-01-17
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
ATE155813T1 (de) 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5334702A (en) 1991-03-25 1994-08-02 University Of Illinois Compositions which are immunologically crossreactive with antibodies and preparative methods therefor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
US5665539A (en) 1991-07-12 1997-09-09 The Regents Of The University Of California Immuno-polymerase chain reaction system for antigen detection
US6391590B1 (en) 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US6297026B1 (en) 1993-07-26 2001-10-02 Cor Therapeutics Inc. Nucleic acids encoding the C140 receptor
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5632994A (en) * 1994-06-14 1997-05-27 La Jolla Cancer Research Foundation Fas associated proteins
US5747245A (en) * 1994-06-14 1998-05-05 La Jolla Cancer Research Foundation Nucleic acids encoding Fas associated proteins and screening assays using same
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6497881B1 (en) 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5995311A (en) 1996-04-30 1999-11-30 Texas Instruments Incorporated Head switch sequence to protect magneto-resistive (MR) head
NZ519191A (en) 1996-10-18 2005-04-29 Univ Texas Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies
US5922553A (en) 1996-11-21 1999-07-13 Trustees Of The University Of Pennsylvania Method of detecting protein by immuno RNA
US6265535B1 (en) * 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1999028347A1 (en) 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
WO1999033965A1 (en) 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
DK1087993T3 (da) 1998-06-18 2008-07-14 Imed Ab Fas-peptider og antistoffer til at modulere apoptose
AU5785999A (en) 1998-08-25 2000-03-14 University Of Washington Streptavidin mutants having secondary functional domains
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6416758B1 (en) 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
SI2803367T1 (en) 1999-06-25 2018-04-30 Immunogen, Inc. Treatment methods with maytansinoid conjugated antibody anti-ERBB
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK1210115T3 (da) 1999-08-27 2009-11-30 Genentech Inc Doseringer til behandling med anti-ErB2-antistoffer
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
US7045286B2 (en) 2000-07-25 2006-05-16 The Trustees Of The University Of Pennsylvania Methods of detecting molecules expressing selected epitopes via fluorescent dyes
US6743592B1 (en) 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US7524628B2 (en) 2000-07-25 2009-04-28 The Trustees Of The University Of Pennsylvania Method for detecting molecules expressing a selected epitope via fluorescent dyes
JP2002114800A (ja) 2000-10-05 2002-04-16 Foundation For Nara Institute Of Science & Technology アポトーシス抑制ペプチド
JP2002138099A (ja) 2000-10-27 2002-05-14 Foundation For Nara Institute Of Science & Technology アポトーシス抑制ペプチド
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
WO2003045309A2 (en) 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
AU2003233662B2 (en) 2002-05-23 2010-04-01 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
ATE536367T1 (de) 2004-02-20 2011-12-15 Univ Pennsylvania Bindende peptidomimetika und deren verwendungen
WO2006116381A2 (en) 2005-04-22 2006-11-02 Imquest Biosciences, Inc. Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
WO2009089362A1 (en) 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Methods of treatment using agents for regulating fas receptor function in skin and hair related pathologies

Also Published As

Publication number Publication date
US20040132641A1 (en) 2004-07-08
CA2490542C (en) 2013-07-16
JP2005534641A (ja) 2005-11-17
AU2003233662B2 (en) 2010-04-01
WO2003099845A3 (en) 2004-04-15
EP1513543A4 (de) 2006-05-31
DE60334452D1 (de) 2010-11-18
AU2003233662A1 (en) 2003-12-12
US8680047B2 (en) 2014-03-25
US7288519B2 (en) 2007-10-30
WO2003099845A2 (en) 2003-12-04
JP4405916B2 (ja) 2010-01-27
US20120245081A1 (en) 2012-09-27
EP1513543B1 (de) 2010-10-06
US8022176B2 (en) 2011-09-20
US20080153742A1 (en) 2008-06-26
CA2490542A1 (en) 2003-12-04
EP1513543A2 (de) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
ATE483466T1 (de) Fas peptid-mimetika und ihre verwendungszwecke
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
MY140010A (en) Purine compounds and use thereof as cannabinoid receptor ligands
MXPA05007938A (es) Ligandos de receptores de cannabinoides y usos de los mismos.
TW200503723A (en) Cannabinoid receptor ligands and uses thereof
MXPA05013294A (es) Ligandos del receptor de cannabinoides y usos de los mismos.
ZA200608607B (en) Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
ATE442850T1 (de) Kappa-opioid-rezeptor-liganden
MXPA05011362A (es) Ligandos de receptor cannabinoide y usos de los mismos.
TW200510419A (en) Cannabinoid receptor ligands and uses thereof
ME02002B (me) Humana monoklonska antitela prema proteinskoj tirozin kinazi 7 (ptk 7) i njihova upotreba
RS51821B (en) NEW COMBINED USE OF SULFONAMIDE UNITS IN CANCER TREATMENT
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
NO20071613L (no) Forbindelser for myokardial perfusjons-billeddannelse
NO20011360L (no) Granul¶rt produkt
AU302706S (en) Activity mat
TNSN05330A1 (en) Tablet comprising fluvastatin and carmellose calcium
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
FR2888041B1 (fr) Plaque active d'ecran plat
ITMI20040230A1 (it) Composti ad attivita' antitumorale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties